Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR2 | O43603 | 7/20 | 0.50 |
| ▸ | GALR1 | P47211 | 5/20 | 0.50 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6795082 | 0.87 | ACHE (0.54) | TSHRLMNAHTR2CMAPTHTR2A | |
| SCHEMBL8403164 | 0.85 | HTT (0.42) | GALR2GALR1DCTPP1TSHRLMNA | |
| SCHEMBL3246394 | 0.81 | MAPT (0.57) | GALR2GALR1IGF1RLMNAJAK2 | |
| SCHEMBL5447231 | 0.80 | IDH2 (0.48) | DCTPP1LMNAJAK2JAK3PTK2 | |
| SCHEMBL18162563 | 0.79 | PKM (0.52) | LMNAMAPTMEN1HTTKMT2A | |
| SCHEMBL3242771 | 0.78 | LMNA (0.49) | GALR2GALR1LMNAJAK2JAK3 | |
| SCHEMBL8263323 | 0.78 | GALR2 (0.59) | GALR2GALR1HTR2CMAPTMEN1 | |
| SCHEMBL8096610 | 0.76 | MAPT (0.53) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL3240269 | 0.76 | LMNA (0.52) | GALR2GALR1IGF1RLMNAJAK2 | |
| SCHEMBL8253256 | 0.76 | LMNA (0.52) | GALR2GALR1IGF1RLMNAJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | GALR2 2/4885GALR1 3/4885DCTPP1 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.